Management of metabolic syndrome: statins

Antonios M Xydakis; Christie M Ballantyne

doi:10.1016/j.ecl.2004.03.011

Management of metabolic syndrome: statins

Endocrinol Metab Clin North Am. 2004 Sep;33(3):509-23, vi. doi: 10.1016/j.ecl.2004.03.011.

Authors

Antonios M Xydakis¹, Christie M Ballantyne

Affiliation

¹ Division of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

PMID: 15262294
DOI: 10.1016/j.ecl.2004.03.011

Abstract

Individuals who have the metabolic syndrome are at increased risk for cardiovascular disease. Combined dyslipidemia is an important component of metabolic syndrome, contributing to excess cardiovascular risk. Lifestyle and pharmacologic interventions are warranted for effective management of this syndrome. This article discusses the current evidence supporting the use of statins and their beneficial impact on lipid and nonlipid aspects of metabolic syndrome-related pathology.

Publication types

Review

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipidemias / drug therapy*
Metabolic Syndrome / drug therapy*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors